TPIDB > 臨床試驗主持人
臨床試驗主持人
更新時間：2023-09-19
陳訓徹Chen, Shin-Cheh
- 計畫主持人
- 執行臨床試驗年資 22 年 9 個月
-
chensc@cgmh.org.tw
發表文獻
10筆
1
Yang JR, Kuo WL, Yu CC, Chen SC, Huang JJ. Reconstructive outcome analysis of the impact of neoadjuvant chemotherapy on immediate breast reconstruction: a retrospective cross-sectional study. BMC Cancer. 2021; 21(1):522.
2
Wang YH, Chan YT, Hung TH, Hung JT, Kuo MW, Wang SH, Chen SC, et al. Transmembrane and coiled-coil domain family 3 (TMCC3) regulates breast cancer stem cell and AKT activation. Oncogene. 2021; 40(16):2858-71.
3
Toi M, Inoue K, Masuda N, Iwata H, Sohn J, Park I, Chen SC, et al. Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2‐ advanced breast cancer: MONARCH 2 & 3 trials. Cancer Science. 2021; 112(6):2381-2392
4
Lu YS, Lee KS, Chao TY, Tseng LM, Chitapanarux I, Chen SC, et al. A Phase Ib Study of Alpelisib or Buparlisib Combined with Tamoxifen Plus Goserelin in Premenopausal Women with HR-Positive HER2-Negative Advanced Breast Cancer. Clin Cancer Res. 2021; 27(2):408-17.
5
Liu Y-L, Kuo W-L, Lo Y-F, Tsai H-P, Shen S-C, Yu C-C, Chen SC, et al. Breast Cancer Larger Than 2.5 cm with Tumor-Free Radioisotope-Hot Sentinel Nodes Has Higher Risk of Non-Hot Axillary Lymph Node Metastasis. Biomedical Journal. 2021.
6
Lin YC, Cheng HH, Chen SC, Shen WC, Huang YT. Pre-treatment high body mass index is associated with poor survival in Asian premenopausal women with localized breast cancer. J Cancer. 2021; 12(15):4488-96.
7
Huang CS, Yang Y, Kwong A, Chen SC, Tseng LM, Liu MC, et al. Trastuzumab emtansine (T-DM1) versus trastuzumab in Chinese patients with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy for HER2-positive breast cancer in the phase 3 KATHERINE study. Breast Cancer Res Treat. 2021; 187(3):759-68.
8
Hamilton E, Cortes J, Ozyilkan O, Chen SC, Petrakova K, Manikhas A, et al. nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer. Clin Breast Cancer. 2021; 21(3):181-90. e2.
9
Chou HH, Chung WS, Ding RY, Kuo WL, Yu CC, Tsai HP, Chen SC, et al. Factors affecting locoregional recurrence in breast cancer patients undergoing surgery following neoadjuvant treatment. BMC Surg. 2021; 21(1):160.
10
Yu CC, Kuo WL, Shen SC, Chou HH, Lo YF, Yu MC, Chen SC, et al. Prognostic study for isolated local recurrence operated with salvage excision in hormone-receptor-positive patients with invasive breast cancer after primary breast surgery. Biomed J. 2020; 43(1):83-93.
